HPV

Trial combines novel therapies for head and neck cancer

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

Study seeks to refine head and neck cancer treatment options

A new robot with a flexible camera and three different surgical instruments will allow more targeted surgeries for patients with head and neck cancers.

New robot enhances accuracy of head, neck cancer surgeries

Vanderbilt-Ingram Cancer Center calls for action to get cancer-preventing HPV vaccination back on track

A significant reduction in annual well visits and immunizations during the COVID-19 pandemic has led to a vaccination gap among U.S. children and adolescents, especially with the human papillomavirus (HPV) vaccine for cancer prevention.

Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform

Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.

Symposium explores prevention of HPV-associated cancers

Physicians and researchers from across the country came to the Vanderbilt Symposium on HPV Infections and Associated Cancers on March 1 to discuss screening and prevention strategies for the human papillomavirus (HPV).

1 2